U.S. bill highlights Clearmind (Nasdaq: CMND) MEAI for veteran treatment access

Rhea-AI Filing Summary

Clearmind Medicine reports that its proprietary compound MEAI (5-MeO-AI), a next-generation, non-hallucinogenic neuroplastogen, has been specifically named in new bipartisan U.S. legislation, the Expanding Veterans’ Access to Emerging Treatments Act of 2026 (H.R. 7091).

The bill would direct the U.S. Department of Veterans Affairs to create investigational research and extended access treatment programs using emerging therapies for unmet medical needs in veterans. Covered therapies include psilocybin, MDMA, MEAI, 5-MeO-DMT, ibogaine, ketamine and others designated by the VA Secretary.

This is the first time MEAI has been referenced in U.S. federal legislation. Clearmind highlights potential applications for conditions such as Alcohol Use Disorder and post-traumatic stress disorder, emphasizing growing policy recognition of innovative, evidence-based psychedelic and neuroplastogen approaches.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: February 2026

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on February 3, 2026, titled “Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments”.

The first three paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: February 3, 2026	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

Exhibit 99.1

Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

This is the first time MEAI, Clearmind’s next-generation, non-hallucinogenic neuroplastogen, has been named in U.S. federal legislation

Vancouver, Canada, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today welcomes the inclusion of its proprietary compound, MEAI (5-methoxy-2-aminoindane,or5-MeO-AI ), in newly introduced bipartisan legislation in the U.S. Congress.

The Expanding Veterans’ Access to Emerging Treatments Act of 2026 (H.R. 7091) directs the Department of Veterans Affairs (VA) to establish an investigational research and extended access treatment program for innovative and emerging therapies that address unmet medical needs in veterans.

Covered therapies explicitly include psilocybin, MDMA, MEAI (5-MeO-AI), 5-MeO-DMT, ibogaine, ketamine, and others as designated by the Secretary of Veterans Affairs. This marks the first time MEAI, Clearmind’s proprietary, next-generation, non-hallucinogenic neuroplastogen, has been named in U.S. federal legislation. If passed, H.R. 7091 would transform clinical treatment across a variety of covered conditions, including Alcohol Use Disorder, by developing VA-supported clinical trials and extended access protocols using these emerging treatments.

“We so greatly appreciate Congress introducing H.R. 7091, which offers a transformational opportunity for veterans suffering from alcoholism, post-traumatic stress disorder and other conditions to access emerging, promising therapies. We also appreciate the recognition of MEAI, a non-hallucinogenic neuroplastogen with the transformative potential to improve the health of veterans,” said Clearmind Medicine CEO Dr. Adi Zuloff-Shani, PhD. “We believe, this bipartisan milestone in Washington, D.C., underscores growing support for innovative, evidence-based approaches to conditions like post-traumatic stress disorder, which remains a significant challenge for many veterans.”

“This bill, with the inclusion of MEAI and other innovative therapies, forges a new vocabulary for evidence-based psychedelic healing,” said Melissa Lavasani, Founder and CEO of the Washington, D.C, non-profit Psychedelic Medicine Coalition.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com

Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how H.R. 7091, if passed, would transform clinical treatment across a variety of covered conditions, including Alcohol Use Disorder, by developing VA-supported clinical trials and extended access protocols using these emerging treatments, how MEAI has the transformative potential to improve the health of veterans and the growing support for innovative, evidence-based approaches to conditions like post-traumatic stress disorder. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

What did Clearmind Medicine (CMND) disclose in this Form 6-K?

Clearmind Medicine reported that its proprietary compound MEAI has been named in new bipartisan U.S. legislation, H.R. 7091. The bill seeks to expand veterans’ access to emerging treatments through Department of Veterans Affairs research and extended access programs for innovative therapies.

What is MEAI in Clearmind Medicine’s pipeline and how is it described?

MEAI is described as Clearmind’s proprietary, next-generation, non-hallucinogenic neuroplastogen. The company develops MEAI and related compounds as novel psychedelic-derived therapeutics aimed at addressing under-treated health problems, including alcohol use disorder, through regulated medicines, foods, or supplements.

What is the Expanding Veterans’ Access to Emerging Treatments Act of 2026 (H.R. 7091)?

H.R. 7091 is bipartisan U.S. legislation directing the Department of Veterans Affairs to establish investigational research and extended access treatment programs. It targets innovative and emerging therapies that address unmet medical needs in veterans across multiple conditions, including Alcohol Use Disorder and post-traumatic stress disorder.

How does H.R. 7091 specifically relate to Clearmind Medicine’s MEAI compound?

The bill explicitly lists MEAI (5-MeO-AI) among covered emerging therapies, alongside psilocybin, MDMA, 5-MeO-DMT, ibogaine, ketamine and others. This marks the first time MEAI has appeared in U.S. federal legislation, signaling growing policy recognition of Clearmind’s proprietary compound.

Which veteran conditions could potentially be addressed under H.R. 7091 using emerging therapies?

The legislation targets conditions with unmet medical needs in veterans, including Alcohol Use Disorder and post-traumatic stress disorder. It contemplates Department of Veterans Affairs-supported clinical trials and extended access protocols using emerging treatments such as MEAI and other listed psychedelic or neuroactive compounds.

How does Clearmind Medicine describe its broader business focus and intellectual property?

Clearmind describes itself as a clinical-stage psychedelic pharmaceutical biotech company focused on novel psychedelic-derived therapeutics for underserved conditions, including alcohol use disorder. It reports an intellectual property portfolio of nineteen patent families and 31 granted patents, with plans to seek additional protection where appropriate.